Healthcare Industry News: radiation therapy
News Release - July 30, 2014
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as PresidentWESTFORD, Mass., July 30, 2014 -- (Healthcare Sales & Marketing Network) -- Cynosure, Inc. (CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that the Board of Directors has promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to President of the Company, effective August 1, 2014. Baker, 53, will continue to serve as CFO and will take the title of President from Michael Davin, who remains Chairman and Chief Executive Officer.
"Tim has been a valued member of Cynosure's leadership team since joining the Company as Executive Vice President and CFO in 2004," Davin said. "He is focused on continuously improving our financial and operating performance and committed to delivering value for our shareholders. Tim played a key strategic role in our June 2013 acquisition of Palomar Medical Technologies; his operational skills and business expertise were keys to successfully completing the integration in just 12 months. We congratulate Tim on this well-deserved promotion."
Before joining Cynosure, Baker served as Vice President, Finance at Stryker Biotech, a division of medical products and services provider Stryker Corporation. From July 2000 to June 2003, Baker served as President and Chief Financial Officer at Photoelectron Corp., a provider of miniature X-ray systems for radiation therapy. From January 1996 to July 2000, he served as Chief Financial Officer and Vice President of Operations at Radionics, Inc., a provider of surgical devices. Baker is a certified public accountant and holds an MBA in operations management.
About Cynosure, Inc.
Cynosure develops and markets laser and light-based aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.